Risk of Long-term Care Admissions Among Medicare Patients Treated with Pimavanserin or Other Atypical Antipsychotics for Parkinson’s Disease Psychosis
Objective: To examine all-cause long-term care (LTC) admission risk among PDP patients treated with atypical antipsychotic (AAP). Background: Risk of LTC-admissions associated with off-label AAPs…Motor-Related and Cognition-Related Safety of Pimavanserin in Patients with Parkinson’s Disease Psychosis (PDP)
Objective: Evaluate motor- and cognition-related safety in pimavanserin-treated patients with PDP. Background: Pimavanserin, a selective 5-HT2A inverse agonist/antagonist, is the only US FDA-approved treatment for…Psychosis in Parkinson’s disease and polymorphisms of the HOMER1 and COMT genes: Is there an association?
Objective: To investigate if polymorphisms of the HOMER1 and COMT gene are associated with psychosis in Parkinson’s disease (PD). Background: Psychosis is one of the…Alteration of lysosomal enzymatic activities in blood of patients with schizophrenia
Objective: To estimate whether alteration of lysosomal activities contributes to schizophrenia (SCZ) pathogenesis, age at onset and risk of developing the disease. Background: SCZ is…Antipsychotic use in Parkinson’s disease: a single center retrospective chart review
Objective: To assess the prevalence of antipsychotic (AP) use in people with Parkinson’s disease (PwP), and identify factors associated with AP prescription and differences in…Longitudinal study of clinical symptoms associated with psychosis in Parkinson’s disease without dementia
Objective: Examine clinical features associated with psychosis among Parkinson’s disease (PD) patients without dementia. Background: Previously identified risk factors for PD psychosis include duration and…A dose-response study of the effect of the mGlu2/3 orthosteric antagonist LY-341,495 on the anti-dyskinetic and anti-psychotic effect of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset
Objective: To assess the effects of different doses of the metabotropic glutamate 2 and 3 (mGlu2/3) orthosteric antagonist (OA) LY-341,495 on the anti-dyskinetic and anti-psychotic…Evaluation of the effect of adding a mGlu2/3 orthosteric antagonist to a highly selective 5-HT2A antagonist on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset
Objective: To determine whether the therapeutic effect of serotonin 2A (5-HT2A) receptor antagonism on dyskinesia and psychosis may be reversed by orthosteric antagonism of metabotropic…Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study
Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis
Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 12
- Next Page »